Pediatric Cancer
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
Pediatric Cancer Study Spells Out Structural Variant Risk Contributors
Researchers unearthed rare germline structural variants involved in pediatric solid tumor risk by analyzing genome sequences from patients, parents, and adult control individuals.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
Childhood Acute Lymphoblastic Leukemia Subtypes, Prognostic Features Uncovered in Genomic Study
Researchers identified 15 subtypes of T-lineage ALL, along with mutation, expression, and regulatory shifts providing development and prognostic clues.
In a Nature Medicine paper, WGS yielded a clinical benefit for 24 percent of pediatric cancer patients, and directly changed clinical management for 7 percent.